Forte Biosciences, Inc. (FBRX) is a publicly traded company in the Unknown sector. Across all available filings, 7 corporate insiders have executed 62 transactions totaling $4.8M, demonstrating a bearish sentiment with -$4.1M in net insider flow. The most recent transaction on Oct 1, 2025 involved a transaction of 1,250 shares valued at $0.
No significant insider buying has been recorded for FBRX in the recent period.
No significant insider selling has been recorded for FBRX in the recent period.
Based on recent SEC filings, insider sentiment for FBRX is bearish with an Insider Alignment Score of 8/100 and a net flow of -$4.1M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Forte Biosciences, Inc. (FBRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 7 insiders are actively trading FBRX stock, having executed 62 transactions in the past 90 days. The most active insider is Paul A. Wagner (Executive), who has made 30 transactions totaling $4.9M.
Get notified when executives and directors at FBRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 1, 2025 | A. Wagner Paul | Executive | Option Exercise | 1,250 | $N/A | $0 | |
| Oct 1, 2025 | A. Wagner Paul | Executive | Payment | 98 | $14.52 | $1.4K | |
| Oct 1, 2025 | A. Riley Antony | Executive | Option Exercise | 375 | $N/A | $0 | |
| Oct 1, 2025 | A. Riley Antony | Executive | Payment | 134 | $14.52 | $1.9K | |
| Jul 1, 2024 | A. Wagner Paul | Executive | Option Exercise | 31,250 | $N/A | $0 | |
| Jul 1, 2024 | A. Wagner Paul | Executive | Payment | 2,453 | $0.55 | $1.3K | |
| Jul 1, 2024 | A. Riley Antony | Executive | Option Exercise | 9,375 | $N/A | $0 | |
| Jul 1, 2024 | A. Riley Antony | Executive | Payment | 3,345 | $0.55 | $1.8K | |
| Apr 1, 2024 | A. Wagner Paul | Executive | Payment | 2,453 | $0.71 | $1.7K | |
| Apr 1, 2024 | A. Wagner Paul | Executive | Option Exercise | 31,250 | $N/A | $0 | |
| Apr 1, 2024 | A. Riley Antony | Executive | Payment | 3,345 | $0.71 | $2.4K | |
| Apr 1, 2024 | A. Riley Antony | Executive | Option Exercise | 9,375 | $N/A | $0 | |
| Jan 1, 2024 | A. Wagner Paul | Executive | Option Exercise | 31,250 | $N/A | $0 | |
| Jan 1, 2024 | A. Wagner Paul | Executive | Payment | 4,109 | $0.82 | $3.4K | |
| Jan 1, 2024 | A. Riley Antony | Executive | Option Exercise | 9,375 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 3 | $4.5M | 78.5% |
Award(A) | 6 | $785.0K | 13.8% |
Purchase(P) | 16 | $377.5K | 6.7% |
Payment(F) | 18 | $50.8K | 0.9% |
Exercise(M) | 19 | $4.8K | 0.1% |
Insider selling pressure at Forte Biosciences, Inc. has increased, with 7 insiders executing 62 transactions across all time. Total sales of $4.5M significantly outpace purchases of $377.5K, resulting in a net outflow of $4.1M. This selling activity appears largely discretionary, which may warrant closer attention from investors.